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Clinically Amendable, Defined, and Rapid Induction of
Human Brain Organoids from Induced Pluripotent Stem
Cells
Eva Tomaskovic-Crook and Jeremy M. Crook
Abstract
Human brain organoids provide opportunities to produce three-dimensional (3D) brain-like tissues for
biomedical research and translational drug discovery, toxicology, and tissue replacement. Here we describe
a protocol for rapid and defined induction of brain organoids from human induced pluripotent stem cells
(iPSCs), using commercially available culture and differentiation media and a cheap, easy to handle and
clinically approved semisynthetic hydrogel. Importantly, the methodology is uncomplicated, well-defined,
and reliable for reproducible and scalable organoid generation, and amendable to principles of current good
laboratory practice (cGLP), with the potential for prospective adaptation to current good manufacturing
practice (cGMP) toward clinical compliance.
Keywords Brain organoid, Clinical compliance, Defined, GelMA, Human induced pluripotent stem
cells, Hydrogel
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Introduction
The ability to generate three-dimensional (3D) organoids in vitro
that recapitulate features of the developing prenatal human brain
in utero represents a quantum leap from conventional 2D neural
cell culture. Whether they incorporate multiple brain regions as
reported by Lancaster and colleagues [1, 2] or are comparatively
simpler [3], they exhibit a remarkable level of complexity unattainable with cells in 2D. While current methods are unable to
precisely recapitulate the complicated patterning and diverse environmental cues found in and experienced by an intact embryo,
they are nonetheless rapidly evolving from first-generation systems
to more defined, standardized, reproducible, and clinically amendable protocols, vital for experimentation and translational application [4]. In addition, with the need to model development and
disease pathogenesis later as well as early in fetal development,
extended culture for organoid maturation is necessary.
Here we describe in detail a method to generate human brain
organoids for protracted culture and maturation, under defined
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conditions, amendable to cGLP and adaptable to cGMP for clinical
compliance. Similar to other protocols for producing organoids
described in this volume, a desired level of quality assurance
(QA) can be applied for all aspects of the method, including but
not limited to the manufacture, procurement, receipt, storage and
handling of materials, reagents and iPSCs, as well as cell and organoid culture. While other guidances specifically consider QA for
many of the abovementioned processes [5–7], in any event, standardized and reliable protocols are necessary for basic science
through applied research and clinical product development.
This chapter details methods that are suitable for routine
application, high-quality research, and adaptable for clinical compliance. The culture media used include commercially available
cGMP, defined feeder-free and serum-free maintenance medium
for human iPSCs, and similarly defined off-the-shelf serum-free
medium for initial neural induction and end-stage differentiation
medium for organoid formation. Importantly, iPSCs are differentiated, and organoids are maintained on a soft hydrogel substrate
produced from photocrosslinkable gelatin methacrylate (GelMA),
a derivative of collagen widely used for biomedical applications
[8]. Finally, the protocol described is scalable to generate larger
numbers of organoids.
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Materials

2.1 iPSC Culture and
Passaging

1. iPSCs.
2. Corning® Matrigel® (hESC qualified matrix, LDEV-free; Falcon, In Vitro Technologies, Cat. no. FAL354277).
3. Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12
(DMEM/F-12; Gibco, Life Technologies, Cat. no. 11330057).
4. mTeSR1 complete kit for hES maintenance (STEMCELL Technologies, Cat. no. 05850).
5. Dulbecco’s phosphate-buffered saline, without Ca2+ and Mg2+
(PBS; Sigma Aldrich, Cat. no. D8537).
6. Ethylenediaminetetraacetic acid (EDTA; Sigma Aldrich, Cat.
no. E8008).

2.2 Preparation of
Cast Hydrogel

1. Gelatin methacrylate (GelMA, bloom 300, 80% degree of substitution, Sigma-Aldrich, Cat. no. 900496) or prepared as
described elsewhere (see Note 6).
2. Irgacure 2959 (2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2methyl-1-propanone; CIBA Chemicals, Cat. no. 29891301PS04).
3. Dulbecco’s phosphate-buffered saline, without Ca2+ and Mg2+
(PBS; Sigma Aldrich, Cat. no. D8537).
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4. 100% ethanol (Chem-Supply, Cat. no. EA043).
5. DMEM/F-12 medium (Gibco, Life Technologies, Cat. no. 11330057).
2.3 Neural Induction
of iPSCs: Generation of
Neural Progenitor Cells

1. STEMdiff Neural Induction Medium (STEMCELL Technologies, Cat. no. 05835).

2.4 Differentiation of
iPSC-Derived Neural
Progenitor Cells

1. Neurobasal Medium (Gibco, Life Technologies, Cat. no. 21103049).
2. DMEM/F-12 medium (Gibco, Life Technologies, Cat. no. 11330057).
3. NeuroCult SM1 neuronal supplement (STEMCELL Technologies, Cat. no. 05711).
4. N2 supplement-A (STEMCELL Technologies, Cat. no. 07152).
5. Brain-derived neurotrophic factor (BDNF; Cat. no. AF-450-02;
PeproTech, Lonza).
6. Tris–HCl (Sigma-Aldrich, Cat. no. T5941).
7. Human serum albumin (Sigma-Aldrich, Cat. no. A9511).
8. L-Glutamine (200 mM; Gibco, Life Technologies, Cat. no. 25030081).

2.5 General
Equipment

1. 6-well and 24-well tissue culture plates (Costar, Sigma-Aldrich).
2. Pipetman (micropipette) and tips.
3. Pipet-Aid (motorized pipette) and serological pipettes.
4. 15 mL conical tubes (Corning, Cat. no. 430052).
5. Parafilm M laboratory film (Edwards Group, Cat. no. PM992).
6. Class 2 Biological Safety Cabinet (biosafety cabinet).
7. Humidified 5% CO2 in air incubator maintained at 37  C.
8. Dry 37  C incubator.
9. Inverted phase-contrast microscope.
10. Low-speed centrifuge.
11. Liquid nitrogen storage tank.
12. 80  C freezer.
13. Refrigerator.
14. UV light source (365 nm range).
15. Luminometer.
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Methods

3.1 Routine iPSC
Culture and Passaging

Reagent preparation and cell culture work should be performed in a
biosafety cabinet unless otherwise specified. All media and reagents
should remain sterile. Incubations and culturing should be performed in a 37  C incubator with a humidified atmosphere of 5%
CO2 in air. Centrifuge steps are performed at room temperature
(RT).
iPSCs are cultured as feeder-free cultures as in the method outlined
below (see Note 1). Importantly, a good quality iPSC culture with
low spontaneous differentiation is essential for efficient neural
induction.
1. Prepare Corning® Matrigel® matrix as per the manufacturer’s
instructions and store frozen aliquots at -80  C (see Note 2).
2. Thaw Matrigel aliquot at 4  C in refrigerator, 2 h before use.
3. Transfer contents of thawed aliquot to 6 mL DMEM/F-12
media prechilled to 4  C in a sterile 15 mL conical tube. Gently
pipet up and down with a serological pipette to mix contents.
4. Immediately add 1 mL diluted Matrigel matrix per well of
6-well plate. Swirl and rock plate back and forth to evenly
coat the surface of the well. Seal plate edges with Parafilm,
wrap in foil, and transfer to a level shelf within a refrigerator
to incubate overnight at 4  C.
5. The following day, carefully remove Matrigel matrix with serological pipette (without scratching bottom of well) and add
1 mL per well DMEM/F-12 to rinse.
6. Remove and add 2 mL DMEM/F-12 to cover each coated
well. Coated wells may be used immediately on the same day or
prepared up to 2 weeks in advance. If to be stored at 4  C in a
refrigerator, seal plate edges with Parafilm and wrap in foil
before storage.
7. Prepare iPSC culture medium (mTeSR1) as per the manufacturer’s instructions and store at 4  C in refrigerator (see Note
3).
8. Monitor iPSCs daily by viewing under phase-contrast microscope to ensure appropriate timing of passaging and removal of
areas of differentiation prior to passage. iPSCs are passaged
prior to colonies becoming confluent (approximately 60–75%
confluency across well) and when center of each colony has
become dense, but not overgrown. For routine passaging, cells
undergo a 1:6 to 1:12 split ratio.
9. When iPSC colonies are ready to passage, prewarm iPSC culture media, DMEM/F-12 media, PBS, and EDTA solution to
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37  C in dry incubator 1 h before use. Prior to use, allow stored
Matrigel-coated plates to equilibrate to room temperature for
30 min.
10. Just before dissociating cells for passaging, aspirate DMEM/F12 from Matrigel-coated wells and add 2 mL prewarmed iPSC
culture media to each well of 6-well plate and place in humidified 37  C/5% CO2 incubator until ready to seed.
11. Aspirate spent culture media from wells to be passaged. Wash
each well briefly with 1 mL PBS and aspirate PBS solution.
12. To dissociate iPSCs, add 1 mL 0.02% EDTA (see Note 4), and
incubate for 2 min in 37  C/5% CO2 incubator.
13. Once detachment of edge of colonies viewed under phasecontrast microscope has been confirmed, carefully aspirate
EDTA solution.
14. With a 5 mL serological pipette, immediately add 3 mL prewarmed DMEM/F-12 media to a well. While slowly dispensing the contents, scrape the tip of the serological pipette over
the surface of the well to dislodge the cells.
15. Repeat one to two times to dislodge the iPSC colonies, but do
over-pipette cell suspension to ensure dissociation of cell aggregates (approximately 10–20 cells) rather than single cells. Transfer dissociated cell aggregates to a 15 mL conical tube.
16. For routine passaging, plate three wells at a range of seeding
densities to enable optimal passaging approximately every 3–4
days in culture. For example, depending on the iPSC line, cells
may be seeded at a 1:6, 1:10, and 1:20 split ratio. For instance,
to achieve a 1:6 split ratio, add 0.5 mL of dissociated cell
aggregates per well of a 6-well plate prepared earlier (see
Sect. 3.1, Step 10), containing 2 mL prewarmed iPSC culture
media, and stored in humidified 37  C/5% CO2 incubator.
3.2 Preparation of
Cast GelMA Hydrogel

GelMA hydrogels are prepared by directly casting into wells of
standard 24-multiwell culture plates (see Note 5).
1. Freshly prepare 5–10% (w/v) GelMA (see Note 6) with 0.5%
Irgacure 2959 in PBS solution (see Note 7). Dissolve by heating
to 37  C for 1 h and mix well.
2. Add 0.2 mL prepolymerized solution per well of 24-well plate
for casting of hydrogel. Ensure an even coating of the well by
rocking plate back and forth.
3. Immediately crosslink the prepolymerized solution by exposure
of each well to 100 mW/cm2 UV light (365 nm) for 60 s via an
optical fiber connected to a Dymax BlueWave 75 UV spot lamp
(see Note 8).
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4. Immediately following polymerization, add 1 mL PBS to
each well.
5. Soak hydrogel for 2 h at 4  C. Rinse hydrogel twice in PBS.
6. Continue soaking of hydrogel overnight at 4  C.
7. The following day, replace PBS solution with 1 mL DMEM/
F12 media per well.
8. Store pre-made cast hydrogels at 4  C in refrigerator. Seal plate
edges with Parafilm and wrap in foil before storage.
3.3 Surface Seeding
of iPSCs Onto Hydrogel
and Generation of
Neural Progenitor Cells

iPSCs are seeded onto cast hydrogel as dissociated cells in mTeSR1
(see Note 5). Colonies are allowed to attach and expand, before
neural induction using STEMdiff Neural Induction Medium
(Fig. 1).
1. Prewarm DMEM/F-12 and mTeSR1 media for 1 h at 37  C in
dry incubator before use.
2. Pre-made cast hydrogels stored at 4  C are equilibrated to
room temperature for 1 h.
3. Carefully remove DMEM/F-12 media from wells without disturbing cast hydrogel from well.
4. Wash hydrogel in each well of 24-well plate with 1 mL prewarmed DMEM/F-12 media. Allow to incubate for at least
15 min in a 37  C/5% CO2 incubator.
5. Just before dissociating cells for passaging, aspirate DMEM/F12 from wells, and add 1 mL prewarmed iPSC culture media to
each well of 24-well plate containing cast hydrogel, and place in
humidified 37  C/5% CO2 incubator until ready to seed.
6. iPSCs are dissociated with EDTA as described in Sect. 3.1 for
routine iPSC cell culture and dissociation.
7. Following dissociation, using a 2 mL serological pipette, slowly
pipette cell aggregate suspension up and down twice, and seed
dissociated cell aggregates at one drop per well (approximately
50 μL).
8. Return 24-well plate to humidified 37  C/5% CO2 incubator.
Distribute cells across the surface of the hydrogel by moving
plate side to side and front and back (at right angles).
9. Leave plates undisturbed overnight before confirming attachment of cells the following day.

Fig. 1 Schematic for neural induction and differentiation of iPSCs seeded onto hydrogel
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10. Replenish mTeSR1 media cells every 2 days. During media
change, ensure the cells are minimally dislodged by slowly
pipetting to the side of the well.
11. Before and after media change, check attachment of cells to
hydrogel surface and cell clustering by phase-contrast microscopy. Return 24-well plate to humidified 37  C/5% CO2 incubator after media change.
12. On the fourth day after seeding, iPSC colonies are transitioned
to Neural Induction Media (see Note 9). Prewarm STEMdiff
Neural Induction Media for 1 h at 37  C in dry incubator
before use.
13. Carefully remove spent media and add 1 mL STEMdiff Neural
Induction Media to each well. Observe cells with phase-contrast
microscopy. Return 24-well plate to humidified 37  C/5% CO2
incubator.
14. To maintain cultures, perform a half media change every 2–3
days by removal of 0.5 mL of spent media and addition of
0.5 mL STEMdiff Neural Induction Media to each well.
Observe cells with phase-contrast microscopy. Return 24-well
plate to humidified 37  C/5% CO2 incubator.
3.4 Neural
Differentiation of iPSCGenerated Neural
Progenitor Cells

Following neural stem cell induction and proliferation, iPSC-neural
progenitor cells are transitioned to undergo neural differentiation
(Fig. 1).
1. Prepare Neural Differentiation Medium (e.g., 50 mL; see Note
10):
l

Neurobasal Medium: 25 mL

l

DMEM/F-12 medium: 25 mL

l

NeuroCult SM1 neuronal supplement: 500 μL (1% final
conc.)

l

N2 supplement-A: 250 μL (0.5% final conc.)

l

L-Glutamine:

l

500 μL (1 final conc.)

BDNF (250 μg/mL stock; see Note 11): 10 μL (50 ng/mL
final concentration).

2. Prewarm Neural Differentiation Medium at 37  C in dry incubator, 1 h before use (see Note 12).
3. To transition iPSC-neural progenitor cells to undergo neural
differentiation, remove spent Neural Induction Media from
each well. Be particularly careful not to dislodge the cells or
the hydrogel.
4. Slowly add 1 mL prewarmed Neural Differentiation Medium to
each well. Return 24-well plate to humidified 37  C/5% CO2
incubator.
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5. Feed cultures every 3–4 days with a half media change to replenish media. Perform a half media change by removal of 0.5 mL of
spent media and addition of 0.5 mL Neural Differentiation
Medium to each well. Due to evaporation of media over time,
it may be necessary to remove a smaller amount of spent media
(roughly half the residual volume of the media in well). Replace
with 0.5 mL Neural Differentiation Medium.
6. Monitor cultures daily and inspect morphology (semitransparent microspikes on outer surface of neurosphere) and acidity of
media (change media before reaching orange/yellow color).
Continue culture until desired stage of development is reached.
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Notes
1. For complete details of culture, adaptation, and expansion of
pluripotent stem cells, refer to Brehm and Ludwig [9].
2. Refer to supplied Certificate of Analysis for Corning® Matrigel® matrix to prepare appropriate aliquot size using a dilution
factor to achieve 6 mL total volume of diluted matrix.
3. The iPSC colonies are routinely propagated as colonies in
mTeSR1 media. Thaw frozen mTeSR1 supplement overnight
at 4  C. Once thawed, prepare aliquots of mTeSR1 supplement
in working volumes and store at 20  C. Do not refreeze. To
ensure stability of components, keep mTeSR1 medium for up
to 2 weeks at 4  C. Other feeder-independent culture media
systems may also be employed.
4. Although EDTA (0.02% w/v in PBS; 0.5 mM) method of
iPSC dissociation is described, iPSCs may also be dissociated
using other reagents, such as Versene (0.02%, Lonza, Cat.
no. 17-711E).
5. High-throughput production of organoids can be achieved by
seeding and differentiating iPSCs onto either hydrogel cast
into wells of standard plastic-multiwell culture plates or custom
bioprinted hydrogel-multiwell plates.
6. A commercial supplier of GelMA is provided. However, depending on the required application, GelMA monomer can be produced from gelatin (Sigma-Aldrich) with tunable modification of
the methacrylation degree and gel concentration; refer to Nichol
et al. and O’Connel et al. [10, 11].
7. Alternatively, a 10% (w/v) Irgacure 2959 stock solution dissolved in 100% ethanol can be prepared and stored at RT,
wrapped in foil to keep dark. Dilute to final concentration of
0.5% (w/v) in GelMA monomer solution before polymerization. Depending on the application, other photoinitiators, for
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example, VA-086 (2, 20 -azobis[2-methyl-N-(2-hydroxyethyl)
propionamide], Wako Pure Chemical Industries), can be used.
8. Apply UV light through a covered tissue culture plate to maintain sterility. To ensure consistent application of energy of UV
light to polymer solution, measure intensity of light using a
luminometer. Expose each well separately by positioning optical fiber directly over each well.
9. Thaw frozen STEMdiff Neural Induction Medium at room
temperature or overnight at 4  C. To ensure stability of components, keep STEMdiff Neural Induction Medium for up to
2 weeks at 4  C. Once thawed, prepare aliquots in working
volumes and store at 20  C. Do not refreeze.
10. To ensure stability of components, prepare sufficient working
volume of Neural Differentiation Medium for 2–3 weeks of
neural differentiation at any one time. Store at 4  C for 2–3
weeks.
11. To prepare 250 μg/mL BDNF stock solution, dissolve 100 μg
vial of BDNF in 0.4 mL filter-sterilized 5 mM Tris–HCl containing 0.5% human serum albumin, pH 7.6. Store 10 μL
aliquots of 250 μg/mL BDNF stock solution at 80  C. Do
not freeze/thaw vials.
12. Immediately after use, return tube of Neural Differentiation
Medium to 4  C to preserve stability of components.
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